Open AccessKynurenine‐3‐monooxygenase: A new direction for the treatment in different diseases
Author(s) -
Lu Yifei,
Shao Mingmei,
Wu Tao
Publication year - 2020
Publication title -
food science and nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.614
H-Index - 27
ISSN - 2048-7177
DOI - 10.1002/fsn3.1418
Subject(s) - kynurenine , quinolinic acid , kynurenic acid , kynurenine pathway , nicotinamide adenine dinucleotide phosphate , pharmacology , chemistry , monooxygenase , drug target , nicotinamide adenine dinucleotide , enzyme , biochemistry , medicine , tryptophan , nad+ kinase , amino acid , cytochrome p450 , oxidase test
Kynurenine‐3‐monooxygenase (KMO) is an enzyme that relies on nicotinamide adenine dinucleotide phosphate (NADP), a key site in the kynurenine pathway (KP), which has great effects on neurological diseases, cancer, and peripheral inflammation. This review mainly pay attention to the research of KMO mechanism for the treatment of different diseases, and hopes to provide assistance for clinical and drug use. KMO controlling the chief division of the KP, which directly controls downstream product quinolinic acid (QUIN) and indirectly controls kynurenic acid (KYNA), plays an important role in many diseases, especially neurological diseases.